ArticleDrugs - real world outcomes2018
Estimating Prevalence and Healthcare Utilization for Treatment-Resistant Depression in Japan: A Retrospective Claims Database Study.
Article in Drugs - real world outcomes, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06701578 (The Effect of the Safe and Sound Protocol on Depression and Anxiety Symptoms), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of the Safe and Sound Protocol on Depression and Anxiety Symptoms
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Pharmacological interventions for treatment-resistant depression in adults.The Cochrane database of systematic reviews · 2019Pooled it
- Trial
- Review
- Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.Frontiers in cell and developmental biology · 2026Review
- Real-World Antidepressant Treatment Persistence in Children and Adolescents with Major Depressive Disorder in Japan: A Retrospective Nationwide Claims-Based Study.Neuropsychiatric disease and treatment · 2026Article
- Article
- Projecting the 10-year costs of care and mortality burden of depression until 2032: a Markov modelling study developed from real-world data.The Lancet regional health. Western Pacific · 2024Article
- Prospective study of antidepressant treatment of psychiatric patients with depressive disorders: treatment adequacy and outcomes.BMC psychiatry · 2023Article
- Exome-wide association study of treatment-resistant depression suggests novel treatment targets.Scientific reports · 2023Article
- Association of Low-Normal Free T4 Levels With Future Major Depression Development.Journal of the Endocrine Society · 2023Article
- Comorbidity and healthcare utilization in patients with treatment resistant depression: A large-scale retrospective cohort analysis using electronic health records.Journal of affective disorders · 2023Article
- Anti-Inflammatory Treatment Efficacy in Major Depressive Disorder: A Systematic Review of Meta-Analyses.Neuropsychiatric disease and treatment · 2023Review
- Epidemiology of treatment resistant depression among major depressive disorder patients in Israel.BMC psychiatry · 2022Article
- Mortality-causing mechanisms and healthcare resource utilisation of treatment-resistant depression: A six-year population-based cohort study.The Lancet regional health. Western Pacific · 2022Article
- A Southeast Asia Consensus on the Definition and Management of Treatment-Resistant Depression.Neuropsychiatric disease and treatment · 2022Article
- Prevalence and Impact of Treatment-Resistant Depression in Latin America: a Prospective, Observational Study.The Psychiatric quarterly · 2021Observational
- Performance evaluation of case definitions of type 1 diabetes for health insurance claims data in Japan.BMC medical informatics and decision making · 2021Article
- Patterns of hypnotic prescribing for residual insomnia and recurrence of major depressive disorder: a retrospective cohort study using a Japanese health insurance claims database.BMC psychiatry · 2021Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMajor depressive disorders (MDDs) including treatment-resistant depression (TRD) are common disabling conditions, but data on their epidemiology in Japan are limited. This study investigated the incidence, epidemiology, and direct medical costs of TRD and pharmaceutically-treated depression (PTD) in Japan to increase our health economic understanding of this phenotype of MDD.
methodsA retrospective cohort study from a private health insurance claims database estimated the 1-year incidence of PTD and TRD and described the health services used and direct medical costs associated with these conditions.
resultsIn the year from 1 April 2012 through 31 March 2013, we identified 1143 incident PTD cases among 98,552 eligible subjects, i.e. 11.59 cases/1000 patient-years. Of the PTD patients, 51.4% were women. Within the 1-year observation interval 137 patients failed more than two antidepressive treatment approaches and thus developed TRD. Though co-morbid conditions and age were similar among PTD and TRD patients, medical costs per patient (patient-year) during their treatment intervals were 1.01 million JPY (0. 540 million JPY) in the TRD population and 0.643 JPY million JPY (0.645 million JPY) in the PTD population who did not convert into TRD.
conclusionsThis study describes the PTD and TRD patient populations in a large claims database in Japan and highlights an unmet medical need for the treatment of TRD to provide better preventative measures and interventions for the treatment of depression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.